Project Grant R43CA287836
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$211K
Federal Agency
National Cancer Institute
Awardee
Embiosys Inc. (Q9PEK2FTD4H6)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports a two-pronged approach to target triple-negative breast cancer (TNBC). The $403,686 award, effective June 1, 2024 through May 31, 2026, will enable researchers at Rutgers, The State University of New Jersey to:
Explore the use of a targeted hybrid vector called AAVP to deliver human tumor necrosis factor (TNF) to both TNBC tumor cells and associated...
This $622,329 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) is funding research at Virginia Commonwealth University (VCU) to develop an inhibitor called PDZ1i that can prevent metastasis and improve the efficacy of chemotherapy for triple-negative breast cancer (TNBC). The key research objectives include: 1) Formulating the PDZ1i inhibitor for clinical use and characterizing its immunomodulatory effects in suppressing...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (CFDA 93.286 - Discovery and Applied Research for Technological Innovations to Improve Human Health) provides $542,721 to the University of Wisconsin - Madison to develop a novel therapeutic approach for treating triple-negative breast cancer (TNBC).
The key products and services funded under this award include:
Optimizing a ferritin-degrading molecule (DEFER) that can induce TNBC cell death through...
The National Cancer Institute (NCI) awarded a $1,001,029 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Immunova Therapeutics LLC to develop a CD4+ T-cell receptor (TCR) engineered immunotherapy for the treatment of triple-negative breast cancer (TNBC). The key product being developed is a proprietary "CD4 TCR-STEM T cell" therapy that has demonstrated the ability to completely inhibit or eliminate TNBC growth in preclinical mouse models. The funding will support Good...
This federal Project Grant award from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), is funding research to evaluate a small-molecule compound, USCYL01, as a means to enhance the efficacy of immune checkpoint inhibitors (ICIs) for the treatment of triple-negative breast cancer (TNBC). The $400,000 award, spanning February 2025 to January 2026, supports two key objectives: 1) Assessing the toxicity and pharmacokinetic properties of USCYL01, which...
This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer.
The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a...
The National Cancer Institute (NCI) awarded a $474,547 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to the Regents of the University of Michigan to conduct research on targeting metabolic vulnerabilities of triple negative breast cancer (TNBC) stem cells. The research aims to evaluate the efficacy of a potent NQO1-bioactivatable redox cycling compound, IB-DNQ, alone or in combination with SOD1 inhibition, in selectively targeting TNBC cancer stem-like...
This $460,977 Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to identify novel "chemo-neoepitopes" (CNEs) that can be used as immunogens to mobilize tumor-specific CD8+ T cells for immunotherapy against triple-negative breast cancer (TNBC).
The research, conducted by Health Research, Inc. at the Roswell Park Division, aims to: 1) identify candidate CNE peptide sequences generated by...
This $549,536 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop a comprehensive 3D wearable near-infrared spectral tomography (NIRST) system to enhance early prediction of residual cancer burden in breast cancer patients undergoing neoadjuvant chemotherapy. The primary objectives are to integrate flexible circuit strips into a sleek, wearable 64-channel breast interface and apply advanced 3D image reconstruction...
The National Cancer Institute (NCI) awarded a $676,584 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas MD Anderson Cancer Center. The 5-year grant, which began on April 1, 2025, will support research to investigate the co-evolution of cancer cell genomic alterations and their interactions with the tumor microenvironment during metastatic spread of triple-negative breast cancer (TNBC) to multiple organ sites.
The research project aims to...